The Experts below are selected from a list of 411 Experts worldwide ranked by ideXlab platform
Mee Joo Kang - One of the best experts on this subject based on the ideXlab platform.
-
impact of misclassification of Klatskin Tumor on incidence of intra and extrahepatic bile duct cancer a population based national cancer registry study
Annals of Hepato-Biliary-Pancreatic Surgery, 2021Co-Authors: Mee Joo Kang, Jiwon Lim, Sungsik Han, Hyeong Min Park, S Kim, Youngjoo Won, Sangjae ParkAbstract:Introduction Misclassification of Klatskin Tumor as intrahepatic rather than extrahepatic bile duct cancer (eBDC) may overestimate the incidence of intrahepatic BDC (iBDC). However, the effect was insignificant in countries with lower incidence of BDC. Therefore, the impact of misclassified Klatskin Tumor on iBDC and eBDC incidences was analyzed in a high endemic country of BDC. Methods The incidence and topography classification of morphology code "Klatskin Tumor (8162/3)" from 1999 to 2017 were investigated based on data of the Korea Central Cancer Registry, which covers the entire 51.6 million Korean population. For misclassification analysis, all Klatskin Tumor was reclassified as eBDC as proposed in ICD-O-3.2. Results Klatskin Tumor accounted for 13.5% of all 81,414 BDC cases. In the registry, a mean of 59.7% of Klatskin Tumor was classified as iBDC, gradually decreasing from 95.5% to 16.9%. Misclassification led to a 17.3% mean overestimation of iBDC cases and a mean underestimation of 15.0% eBDC cases. After reclassification, iBDC and eBDC constituted 46.4% and 53.6% of all BDC, respectively. Age standardized rate (ASR) of incidence per 100,000 population decreased in iBDC from 3.4 to 2.9 and increased in eBDC from 2.8 to 3.2 after reclassification. Average annual percent change of iBDC and eBDC incidences were 2.0% and 1.2%, respectively, but the ASR of iBDC significantly decreased since 2012 (p < 0.0001). Conclusions Misclassification of Klatskin Tumor has remarkable impact on the incidence of iBDC and eBDC in a highly endemic country. The incidence of iBDC and eBDC increased over time but not linearly.
-
impact of changes in the topographic classification of Klatskin Tumor on incidence of intra and extrahepatic bile duct cancer a population based national cancer registry study
Journal of Hepato-biliary-pancreatic Sciences, 2021Co-Authors: Mee Joo Kang, Jiwon Lim, Sungsik Han, Hyeong Min Park, Youngjoo Won, Sun Whe Kim, Sangjae ParkAbstract:BACKGROUND Misclassification of Klatskin Tumor as intrahepatic rather than extrahepatic bile duct cancer (eBDC) may overestimate the incidence of intrahepatic BDC (iBDC). This study aimed to investigate the impact of misclassified Klatskin Tumor on iBDC and eBDC incidences in Korea, where BDC is highly endemic. METHODS The data of incidence, topography and morphology code of BDC from 1999 to 2017 were obtained from the Korea Central Cancer Registry, which covers the entire 51.6 million Korean population. For misclassification analysis, all Klatskin Tumors were reclassified as eBDC. RESULTS Klatskin Tumors accounted for 13.5% of all 81 414 BDC cases. In the registry, an average of 59.7% of Klatskin Tumors were classified as iBDC, gradually decreasing from 95.5% to 16.9%. Misclassification led to a 17.3% overestimation of iBDC cases and a 15.0% underestimation of eBDC cases on average. After reclassification, age standardized rate (ASR) of incidence per 100 000 population decreased in iBDC from 3.4 to 2.9 and increased in eBDC from 2.8 to 3.2. Average annual percentage change of iBDC and eBDC incidences were 2.0% and 1.2%, respectively, but ASR of iBDC significantly decreased since 2012 (P < 0.0001). CONCLUSIONS Misclassification of Klatskin Tumors has remarkable impact on the incidence of iBDC and eBDC in a highly endemic country.
-
does preoperative portal vein embolization have any impact on the outcome of right side hepatectomy for Klatskin Tumor
Journal of Gastrointestinal Surgery, 2013Co-Authors: Mee Joo Kang, Jinyoung Jang, Wooil Kwon, Jae Woo Park, Ye Rim Chang, S KimAbstract:Background and Aim The clinical usefulness of portal vein embolization (PVE) for Klatskin Tumor is not well established. The authors explored the change in liver volume and function before and after major hepatectomy and evaluated the effect of PVE.
S Kim - One of the best experts on this subject based on the ideXlab platform.
-
impact of misclassification of Klatskin Tumor on incidence of intra and extrahepatic bile duct cancer a population based national cancer registry study
Annals of Hepato-Biliary-Pancreatic Surgery, 2021Co-Authors: Mee Joo Kang, Jiwon Lim, Sungsik Han, Hyeong Min Park, S Kim, Youngjoo Won, Sangjae ParkAbstract:Introduction Misclassification of Klatskin Tumor as intrahepatic rather than extrahepatic bile duct cancer (eBDC) may overestimate the incidence of intrahepatic BDC (iBDC). However, the effect was insignificant in countries with lower incidence of BDC. Therefore, the impact of misclassified Klatskin Tumor on iBDC and eBDC incidences was analyzed in a high endemic country of BDC. Methods The incidence and topography classification of morphology code "Klatskin Tumor (8162/3)" from 1999 to 2017 were investigated based on data of the Korea Central Cancer Registry, which covers the entire 51.6 million Korean population. For misclassification analysis, all Klatskin Tumor was reclassified as eBDC as proposed in ICD-O-3.2. Results Klatskin Tumor accounted for 13.5% of all 81,414 BDC cases. In the registry, a mean of 59.7% of Klatskin Tumor was classified as iBDC, gradually decreasing from 95.5% to 16.9%. Misclassification led to a 17.3% mean overestimation of iBDC cases and a mean underestimation of 15.0% eBDC cases. After reclassification, iBDC and eBDC constituted 46.4% and 53.6% of all BDC, respectively. Age standardized rate (ASR) of incidence per 100,000 population decreased in iBDC from 3.4 to 2.9 and increased in eBDC from 2.8 to 3.2 after reclassification. Average annual percent change of iBDC and eBDC incidences were 2.0% and 1.2%, respectively, but the ASR of iBDC significantly decreased since 2012 (p < 0.0001). Conclusions Misclassification of Klatskin Tumor has remarkable impact on the incidence of iBDC and eBDC in a highly endemic country. The incidence of iBDC and eBDC increased over time but not linearly.
-
does preoperative portal vein embolization have any impact on the outcome of right side hepatectomy for Klatskin Tumor
Journal of Gastrointestinal Surgery, 2013Co-Authors: Mee Joo Kang, Jinyoung Jang, Wooil Kwon, Jae Woo Park, Ye Rim Chang, S KimAbstract:Background and Aim The clinical usefulness of portal vein embolization (PVE) for Klatskin Tumor is not well established. The authors explored the change in liver volume and function before and after major hepatectomy and evaluated the effect of PVE.
Alban Denys - One of the best experts on this subject based on the ideXlab platform.
-
preoperative portal vein embolization alone with biliary drainage compared to a combination of simultaneous portal vein right hepatic vein embolization and biliary drainage in Klatskin Tumor
CardioVascular and Interventional Radiology, 2018Co-Authors: Arnaud Hocquelet, Charalampos Sotiriadis, Rafael Duran, Boris Guiu, Takamune Yamaguchi, Nermin Halkic, Emmanuel Melloul, Nicolas Demartines, Alban DenysAbstract:To compare estimated future remnant liver (FRL) growth following portal vein embolization or liver venous deprivation (LVD) (combined PVE and right hepatic vein embolization), before surgery for a Klatskin Tumor in patients who receive intraoperative biliary drainage or before venous interventional radiology. Six patients underwent LVD and six underwent PVE alone before hepatectomy for a Klatskin Tumor. Before embolization, the FRL ratio, prothrombin time and bilirubin levels were similar in both groups. The FRL was determined before and 3 weeks after embolization by enhanced CT. PVE was performed with n-butyl-2-cyanoacrylate, and the right hepatic vein was embolized with vascular plugs during the same procedure. Biliary drainage was performed percutaneously or by endoscopy. Post-hepatectomy liver function and duration of hospital stay were assessed. There were no adverse events. The median FRL ratio was significantly higher following LVD than after PVE 58% (54–71) and 37% (30–44), respectively, p = 0.017. The FRL volume after embolization was 1.6 times higher after LVD than PVE (p = 0.016). Four and five patients were operated in the LVD and PVE groups, respectively. There was a trend toward a shorter median postoperative hospital stay and 90-day mortality in the LVD versus PVE group: 14 versus 44 days, (p = 0.114) and 0 versus two deaths (p = 0.429), respectively. LVD associated with biliary drainage is safe and results in a better FRL ratio than biliary drainage associated with PVE alone.
Linbo Zhao - One of the best experts on this subject based on the ideXlab platform.
-
placement of i seed strands and stents for a type iv Klatskin Tumor
World Journal of Gastroenterology, 2015Co-Authors: Wen Zhang, Zhengqiang Yang, Haibin Shi, Shen Liu, Weizhong Zhou, Linbo ZhaoAbstract:Herein, we report a new technique that consists of placing two (125)I seed strands and two stents in the right and left intrahepatic bile ducts for the treatment of hilar cholangiocarcinoma. A 75-year-old man presented with jaundice and was diagnosed with Bismuth type IV Klatskin Tumor. Abdominal computed tomography (CT) showed intrahepatic and extrahepatic bile duct dilatation and a soft tissue mass in the hepatic hilum. Because curative surgical resection was not possible, we placed (125)I seed strands and stents in the right and left intrahepatic bile ducts. Three months later, abdominal CT showed less intrahepatic and extrahepatic bile duct dilatation than before the procedure. This technique was feasible and could be considered for the treatment of patients with Bismuth type IV Tumors.
Sangjae Park - One of the best experts on this subject based on the ideXlab platform.
-
impact of misclassification of Klatskin Tumor on incidence of intra and extrahepatic bile duct cancer a population based national cancer registry study
Annals of Hepato-Biliary-Pancreatic Surgery, 2021Co-Authors: Mee Joo Kang, Jiwon Lim, Sungsik Han, Hyeong Min Park, S Kim, Youngjoo Won, Sangjae ParkAbstract:Introduction Misclassification of Klatskin Tumor as intrahepatic rather than extrahepatic bile duct cancer (eBDC) may overestimate the incidence of intrahepatic BDC (iBDC). However, the effect was insignificant in countries with lower incidence of BDC. Therefore, the impact of misclassified Klatskin Tumor on iBDC and eBDC incidences was analyzed in a high endemic country of BDC. Methods The incidence and topography classification of morphology code "Klatskin Tumor (8162/3)" from 1999 to 2017 were investigated based on data of the Korea Central Cancer Registry, which covers the entire 51.6 million Korean population. For misclassification analysis, all Klatskin Tumor was reclassified as eBDC as proposed in ICD-O-3.2. Results Klatskin Tumor accounted for 13.5% of all 81,414 BDC cases. In the registry, a mean of 59.7% of Klatskin Tumor was classified as iBDC, gradually decreasing from 95.5% to 16.9%. Misclassification led to a 17.3% mean overestimation of iBDC cases and a mean underestimation of 15.0% eBDC cases. After reclassification, iBDC and eBDC constituted 46.4% and 53.6% of all BDC, respectively. Age standardized rate (ASR) of incidence per 100,000 population decreased in iBDC from 3.4 to 2.9 and increased in eBDC from 2.8 to 3.2 after reclassification. Average annual percent change of iBDC and eBDC incidences were 2.0% and 1.2%, respectively, but the ASR of iBDC significantly decreased since 2012 (p < 0.0001). Conclusions Misclassification of Klatskin Tumor has remarkable impact on the incidence of iBDC and eBDC in a highly endemic country. The incidence of iBDC and eBDC increased over time but not linearly.
-
impact of changes in the topographic classification of Klatskin Tumor on incidence of intra and extrahepatic bile duct cancer a population based national cancer registry study
Journal of Hepato-biliary-pancreatic Sciences, 2021Co-Authors: Mee Joo Kang, Jiwon Lim, Sungsik Han, Hyeong Min Park, Youngjoo Won, Sun Whe Kim, Sangjae ParkAbstract:BACKGROUND Misclassification of Klatskin Tumor as intrahepatic rather than extrahepatic bile duct cancer (eBDC) may overestimate the incidence of intrahepatic BDC (iBDC). This study aimed to investigate the impact of misclassified Klatskin Tumor on iBDC and eBDC incidences in Korea, where BDC is highly endemic. METHODS The data of incidence, topography and morphology code of BDC from 1999 to 2017 were obtained from the Korea Central Cancer Registry, which covers the entire 51.6 million Korean population. For misclassification analysis, all Klatskin Tumors were reclassified as eBDC. RESULTS Klatskin Tumors accounted for 13.5% of all 81 414 BDC cases. In the registry, an average of 59.7% of Klatskin Tumors were classified as iBDC, gradually decreasing from 95.5% to 16.9%. Misclassification led to a 17.3% overestimation of iBDC cases and a 15.0% underestimation of eBDC cases on average. After reclassification, age standardized rate (ASR) of incidence per 100 000 population decreased in iBDC from 3.4 to 2.9 and increased in eBDC from 2.8 to 3.2. Average annual percentage change of iBDC and eBDC incidences were 2.0% and 1.2%, respectively, but ASR of iBDC significantly decreased since 2012 (P < 0.0001). CONCLUSIONS Misclassification of Klatskin Tumors has remarkable impact on the incidence of iBDC and eBDC in a highly endemic country.